Listing 1 - 7 of 7 |
Sort by
|
Choose an application
Animals -- Research. --- Laboratory animals. --- Government Regulation --- Animal Experimentation --- Animals --- Research.
Choose an application
Animal models in research -- Congresses. --- Nervous system -- Diseases -- Animal models -- Congresses. --- Nervous system --- Animal models in research --- Epidemiologic Study Characteristics as Topic --- Investigative Techniques --- Methods --- Evaluation Studies as Topic --- Drug Discovery --- Research --- Diseases --- Health Care Evaluation Mechanisms --- Epidemiologic Methods --- Science --- Analytical, Diagnostic and Therapeutic Techniques and Equipment --- Quality of Health Care --- Natural Science Disciplines --- Public Health --- Environment and Public Health --- Health Care Quality, Access, and Evaluation --- Disciplines and Occupations --- Health Care --- Research Design --- Nervous System Diseases --- Drug Evaluation, Preclinical --- Clinical Trials as Topic --- Models, Animal --- Medicine --- Health & Biological Sciences --- Neurology --- Animal models
Choose an application
"Biological differences between the sexes influence not only individual health but also public health, biomedical research, and health care. The Institute of Medicine held a workshop March 8-9, 2010, to discuss sex differences and their implications for translational neuroscience research, which bridges the gap between scientific discovery and application ..."--Summary.
Sex factors in disease --- Sex differences --- Health --- Human biology --- Neurosciences --- Research --- Neural sciences --- Neurological sciences --- Neuroscience --- Personal health --- Wellness --- Gender differences --- Sexual dimorphism in humans --- Diseases --- Sex factors --- Medical sciences --- Nervous system --- Biology --- Physical anthropology --- Medicine --- Physiology --- Holistic medicine --- Hygiene --- Well-being --- Sex differentiation --- Pathology
Choose an application
"In 2011 the Grand Challenges in Global Mental Health initiative identified priorities that have the potential to make a significant impact on the lives of people with mental, neurological, and substance use disorders. Reduction of the cost and improvement of the supply of effective medicines was highlighted as one of the top five challenges. For low- and middle-income countries, improving access to appropriate essential medicines can be a tremendous challenge and a critical barrier to scaling up quality care for mental, neurological, and substance use disorders. Reduction of cost and improvement of the supply of effective medicines has the potential to significantly impact the lives of patients with these disorders. Improving Access to Essential Medicines for Mental, Neurological, and Substance Use Disorders in Sub-Saharan Africa is the summary of a workshop convened by the Institute of Medicine Neuroscience Forum in January 2014 in Addis Ababa, Ethiopia to discuss opportunities for achieving long-term affordable access to medicines for these disorders. This report examines challenges and opportunities for improving access to essential medicines in four critical areas: demand, selection, supply chains, and financing and pricing. The report also discusses successful activities that increase access to essential medicines both within Sub-Saharan Africa and in other developing countries, and considers the role of governments, nongovernmental organizations, and private groups in procurement of essential medicines for mental, neurological, and substance use disorders."--
Psychology, Pathological --- Nervous System Diseases --- Mental illness --- drug therapy. --- drug therapy
Choose an application
Glutamate is the most pervasive neurotransmitter in the central nervous system (CNS). Despite this fact, no validated biological markers, or biomarkers, currently exist for measuring glutamate pathology in CNS disorders or injuries. Glutamate dysfunction has been associated with an extensive range of nervous system diseases and disorders. Problems with how the neurotransmitter glutamate functions in the brain have been linked to a wide variety of disorders, including schizophrenia, Alzheimer's, substance abuse, and traumatic brain injury. These conditions are widespread, affecting a large portion of the United States population, and remain difficult to treat. Efforts to understand, treat, and prevent glutamate-related disorders can be aided by the identification of valid biomarkers. The Institute of Medicine's Forum on Neuroscience and Nervous System Disorders held a workshop on June 21-22, 2010, to explore ways to accelerate the development, validation, and implementation of such biomarkers. This book investigates promising current and emerging technologies, and outlines strategies to procure resources and tools to advance drug development for associated nervous system disorders. Moreover, this report highlights presentations by expert panelists, and the open panel discussions that occurred during the workshop.
Neuropharmacology. --- Biochemical markers --- Drug development --- Nervous system --- Neuropharmacology --- Chemistry, Pharmaceutical --- Biological Markers --- Nervous System Diseases --- Investigative Techniques --- Nervous System --- Excitatory Amino Acids --- Pharmacology --- Amino Acids, Dicarboxylic --- Neurosciences --- Amino Acids, Acidic --- Biological Science Disciplines --- Anatomy --- Biological Factors --- Amino Acids --- Diseases --- Chemistry --- Health Occupations --- Analytical, Diagnostic and Therapeutic Techniques and Equipment --- Amino Acids, Peptides, and Proteins --- Natural Science Disciplines --- Disciplines and Occupations --- Chemicals and Drugs --- Biomarkers, Pharmacological --- Drug Discovery --- Glutamic Acid --- Central Nervous System Diseases --- Central Nervous System --- Human Anatomy & Physiology --- Medicine --- Health & Biological Sciences --- Animal Biochemistry --- Medical Research --- Glutamic acid --- Central nervous system --- Pharmacokinetics. --- Diseases.
Choose an application
"Nearly 5.3 million Americans are living with Alzheimer's disease, and 26.6 million people are affected worldwide. The Alzheimer's Disease Neuroimaging Initiative (ADNI), a public-private partnership, provides a publicly available, international database of clinical and imaging data to foster research and collaboration on Alzheimer's research worldwide. The Institute of Medicine held a workshop on July 12, 2010, to explore opportunities to use information from and partnerships formed because of ADNI to continue to improve the understanding and treatment of Alzheimer's disease."--Publisher's description.
Alzheimer's disease --- Alzheimer disease --- Alzheimer's dementia --- Basal ganglia --- Presenile dementia --- Senile dementia --- Imaging. --- Diseases
Choose an application
Mental illness -- Treatment -- Africa, Sub-Saharan. --- Nervous system -- Diseases -- Treatment -- Africa, Sub-Saharan. --- Substance abuse -- Treatment -- Africa, Sub-Saharan. --- Mental illness --- Nervous system --- Substance abuse --- Professional Competence --- Health Services Needs and Demand --- Diseases --- Health Care Quality, Access, and Evaluation --- Health Services Administration --- Regional Health Planning --- Psychiatry and Psychology --- Health Care --- Delivery of Health Care --- Educational Measurement --- Health Planning --- Education --- Health Care Economics and Organizations --- Anthropology, Education, Sociology and Social Phenomena --- Clinical Competence --- Medically Underserved Area --- Substance-Related Disorders --- Nervous System Diseases --- Mental Disorders --- Quality of Health Care --- Public Health --- Health & Biological Sciences --- Mental Illness Prevention --- Treatment
Listing 1 - 7 of 7 |
Sort by
|